Man Group plc Cuts Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Man Group plc decreased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 40.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 36,144 shares of the biopharmaceutical company’s stock after selling 24,377 shares during the quarter. Man Group plc’s holdings in Regeneron Pharmaceuticals were worth $25,746,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in REGN. Capital International Investors increased its position in shares of Regeneron Pharmaceuticals by 41.6% during the fourth quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company’s stock worth $3,373,859,000 after acquiring an additional 1,390,534 shares during the period. Norges Bank purchased a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth approximately $802,036,000. Price T Rowe Associates Inc. MD raised its holdings in Regeneron Pharmaceuticals by 63.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company’s stock valued at $1,485,527,000 after acquiring an additional 810,144 shares in the last quarter. Amundi raised its holdings in shares of Regeneron Pharmaceuticals by 45.8% in the 4th quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company’s stock valued at $1,138,074,000 after purchasing an additional 487,489 shares in the last quarter. Finally, Loomis Sayles & Co. L P grew its stake in shares of Regeneron Pharmaceuticals by 33.4% during the fourth quarter. Loomis Sayles & Co. L P now owns 1,575,349 shares of the biopharmaceutical company’s stock worth $1,122,168,000 after purchasing an additional 393,997 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. Cantor Fitzgerald initiated coverage on Regeneron Pharmaceuticals in a report on Tuesday, April 22nd. They issued an “overweight” rating and a $695.00 price target for the company. Bank of America lowered their target price on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an “underperform” rating on the stock in a research report on Thursday, April 17th. UBS Group lowered their price target on Regeneron Pharmaceuticals from $768.00 to $633.00 and set a “neutral” rating on the stock in a report on Wednesday, April 30th. Citigroup upgraded shares of Regeneron Pharmaceuticals from a “neutral” rating to a “buy” rating and raised their target price for the stock from $600.00 to $700.00 in a research note on Wednesday. Finally, Leerink Partners upgraded shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and raised their price objective for the company from $762.00 to $834.00 in a research report on Wednesday, February 5th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, nineteen have issued a buy rating and three have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $890.60.

Regeneron Pharmaceuticals Trading Up 2.4%

Shares of Regeneron Pharmaceuticals stock opened at $584.99 on Friday. Regeneron Pharmaceuticals, Inc. has a 1 year low of $520.50 and a 1 year high of $1,211.20. The company has a market capitalization of $63.95 billion, a P/E ratio of 15.28, a P/E/G ratio of 2.34 and a beta of 0.43. The business has a 50 day moving average price of $602.44 and a 200 day moving average price of $686.93. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm had revenue of $3.03 billion for the quarter, compared to analyst estimates of $3.40 billion. During the same quarter last year, the business posted $9.55 EPS. The firm’s revenue was down 3.7% compared to the same quarter last year. Sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th will be issued a dividend of $0.88 per share. The ex-dividend date is Tuesday, May 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.60%. Regeneron Pharmaceuticals’s payout ratio is currently 8.96%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.